Biosimilars in the EU

www.ema.europa.eu

neutralise the medicine’s activity and reduce its efficacy. Thus, potential immunogenicity needs to be always evaluated for all biological medicines. Natural variability is inherent to all biological medicines and strict controls are always in place during manufacturing to ensure that it does not affect the way the medicine works or its safety. 7

  Efficacy, Biosimilars, Biosimilars in the eu, Its efficacy